Erschienen in:
02.06.2017 | Original Article
Feasibility of tongue strength measurements during (chemo)radiotherapy in head and neck cancer patients
verfasst von:
Leen Van den Steen, Olivier Vanderveken, Jan Vanderwegen, Dirk Van Gestel, Jean-François Daisne, Johan Allouche, Laurence Delacroix, Diane Van Rompaey, Sylvie Beauvois, Sophie Cvilic, Steven Mariën, Gauthier Desuter, Jan Baptist Vermorken, Danielle Van den Weyngaert, Pol Specenier, Carl Van Laer, Marc Peeters, Paul Van de Heyning, Gilbert Chantrain, Georges Lawson, Cathy Lazarus, Marc De Bodt, Gwen Van Nuffelen, Member of the Belgian Cancer Plan 29_033_Dysphagia Group
Erschienen in:
Supportive Care in Cancer
|
Ausgabe 11/2017
Einloggen, um Zugang zu erhalten
Abstract
Purpose
The aim of this study was to investigate the feasibility of tongue strength measures (TSMs) and the influence of bulb location, sex, and self-perceived pain and mucositis in head and neck cancer (HNC) patients during chemoradiotherapy (CRT).
Methods
Twenty-six newly diagnosed HNC patients treated with CRT performed anterior and posterior maximal isometric tongue pressures by means of the Iowa Oral Performance Instrument (IOPI). The Oral Mucositis Weekly Questionnaire (OMWQ) and a Visual Analogue Scale (VAS) for pain during swallowing were completed weekly from baseline to 1 week post CRT.
Results
Feasibility of TSMs during CRT declines significantly from 96 to 100% at baseline to 46% after 6 weeks of CRT. But post-hoc analyses reveal only significant differences in feasibility between baseline and measurements after 4 weeks of treatment. No effect of gender or bulb location was established, but feasibility is influenced by pain and mucositis.
Conclusions
Feasibility of TSMs declines during CRT and is influenced by mucositis and pain. For the majority of subjects, TSMs were feasible within the first 4 weeks, which provides a window of scientific and clinical opportunities in this patient population.